Virus infection induced pulmonary fibrosis
WJ Huang, XX Tang - Journal of translational medicine, 2021 - Springer
Pulmonary fibrosis is the end stage of a broad range of heterogeneous interstitial lung
diseases and more than 200 factors contribute to it. In recent years, the relationship between …
diseases and more than 200 factors contribute to it. In recent years, the relationship between …
COVID‐19 immunopathology: from acute diseases to chronic sequelae
The clinical manifestation of coronavirus disease 2019 (COVID‐19) mainly targets the lung
as a primary affected organ, which is also a critical site of immune cell activation by severe …
as a primary affected organ, which is also a critical site of immune cell activation by severe …
Infection of lung megakaryocytes and platelets by SARS-CoV-2 anticipate fatal COVID-19
Abstract SARS-CoV-2, although not being a circulatory virus, spread from the respiratory
tract resulting in multiorgan failures and thrombotic complications, the hallmarks of fatal …
tract resulting in multiorgan failures and thrombotic complications, the hallmarks of fatal …
Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) and Coronavirus disease-
2019 (COVID-19), whose etiologic agent is severe acute respiratory syndrome coronavirus …
2019 (COVID-19), whose etiologic agent is severe acute respiratory syndrome coronavirus …
Longitudinal whole blood transcriptomic analysis characterizes neutrophil activation and interferon signaling in moderate and severe COVID-19
C Prebensen, Y Lefol, PL Myhre, T Lüders… - Scientific reports, 2023 - nature.com
A maladaptive inflammatory response has been implicated in the pathogenesis of severe
COVID-19. This study aimed to characterize the temporal dynamics of this response and …
COVID-19. This study aimed to characterize the temporal dynamics of this response and …
Decrease in Angiotensin-Converting Enzyme activity but not concentration in plasma/lungs in COVID-19 patients offers clues for diagnosis/treatment
Although several therapeutics are used to treat coronavirus disease 2019 (COVID-19)
patients, there is still no definitive metabolic marker to evaluate disease severity and …
patients, there is still no definitive metabolic marker to evaluate disease severity and …
Effects of standard-dose prophylactic, high-dose prophylactic, and therapeutic anticoagulation in patients with hypoxemic COVID-19 pneumonia: the ANTICOVID …
Importance Given the high risk of thrombosis and anticoagulation-related bleeding in
patients with hypoxemic COVID-19 pneumonia, identifying the lowest effective dose of …
patients with hypoxemic COVID-19 pneumonia, identifying the lowest effective dose of …
Co-infection associated with SARS-CoV-2 and their management
SARS-CoV-2 was discovered in Wuhan, China and quickly spread throughout the world.
This deadly virus moved from person to person, resulting in severe pneumonia, fever, chills …
This deadly virus moved from person to person, resulting in severe pneumonia, fever, chills …
Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
E Gavriilidis, C Antoniadou, A Chrysanthopoulou… - Clinical …, 2022 - Elsevier
Aiming to reduce mortality in COVID-19 with severe respiratory failure we administered a
combined rescue treatment (COMBI) on top of standard-of-care (SOC: dexamethasone …
combined rescue treatment (COMBI) on top of standard-of-care (SOC: dexamethasone …
Differential activation of programmed cell death in patients with severe SARS-CoV-2 infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe lower
airway disease and death in a subset of patients. Knowledge on the relative contribution of …
airway disease and death in a subset of patients. Knowledge on the relative contribution of …